Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-7367 in Combination With Anti-tumor Agents in Solid Tumors
NCT07229586Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-7367 in solid tumor, sponsored by Hengrui Therapeutics. Started Dec 2025; status: recruiting.
02
Drugs
SHR-7367
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07229586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229586.